| Medical and Health Sciences | 2021-2025 | 719 | GB 69 | 99.84 |
| Biological Sciences | 2021-2025 | 734 | GB 30 | 99.23 |
| Oncology | Lifetime | 205 | GB 15 | 99.67 |
| Otolaryngology | Lifetime | 27 | GB 2 | 99.63 |
| Genetics | Lifetime | 256 | GB 27 | 99.40 |
| Pulmonary and Respiratory Medicine | Lifetime | 749 | GB 50 | 98.87 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 806 | GB 75 | 97.83 |
| Immunology | Lifetime | 902 | GB 60 | 96.92 |
| Biotechnology | Lifetime | 347 | GB 17 | 95.26 |
| Radiation Physics | Lifetime | 704 | GB 63 | 88.82 |
| Otolaryngology | 2021-2025 | 10 | GB 2 | 99.60 |
| Oncology | 2021-2025 | 83 | GB 4 | 99.47 |
| Immunology | 2021-2025 | 153 | GB 6 | 96.74 |
| Genetics | 2021-2025 | 178 | GB 25 | 95.25 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 613 | GB 38 | 92.88 |
| Head and Neck Cancer Studies | Lifetime | 13 | GB 1 | 99.89 |
| Cancer Research and Treatments | Lifetime | 22 | GB 2 | 99.77 |
| Virus-based gene therapy research | Lifetime | 34 | GB 2 | 99.79 |
| Cancer Diagnosis and Treatment | Lifetime | 35 | GB 3 | 99.60 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 81 | GB 2 | 99.78 |
| CAR-T cell therapy research | Lifetime | 71 | GB 3 | 99.69 |
| Lung Cancer Treatments and Mutations | Lifetime | 224 | GB 9 | 99.41 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 196 | GB 12 | 98.64 |
| RNA Interference and Gene Delivery | Lifetime | 391 | GB 16 | 98.87 |
| Oral health in cancer treatment | Lifetime | 55 | GB 5 | 98.29 |
| Head and Neck Surgical Oncology | Lifetime | 290 | GB 13 | 98.59 |
| Viral gastroenteritis research and epidemiology | Lifetime | 545 | GB 43 | 98.46 |
| interferon and immune responses | Lifetime | 324 | GB 23 | 97.82 |
| Immunotherapy and Immune Responses | Lifetime | 973 | GB 65 | 98.53 |
| Peptidase Inhibition and Analysis | Lifetime | 622 | GB 38 | 97.91 |
| Viral Infectious Diseases and Gene Expression in Insects | Lifetime | 473 | GB 28 | 96.76 |
| Brain Metastases and Treatment | Lifetime | 391 | GB 4 | 97.39 |
| Dysphagia Assessment and Management | Lifetime | 409 | GB 30 | 96.45 |
| Lung Cancer Research Studies | Lifetime | 951 | GB 37 | 96.97 |
| Salivary Gland Tumors Diagnosis and Treatment | Lifetime | 568 | GB 30 | 96.61 |
| Colorectal and Anal Carcinomas | Lifetime | 697 | GB 50 | 96.15 |
| PARP inhibition in cancer therapy | Lifetime | 702 | GB 59 | 92.84 |
| Head and Neck Cancer Studies | 2021-2025 | 6 | GB 1 | 99.76 |
| Virus-based gene therapy research | 2021-2025 | 7 | GB 1 | 99.08 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 103 | GB 2 | 99.59 |
| interferon and immune responses | 2021-2025 | 52 | GB 3 | 96.72 |
| Cancer Diagnosis and Treatment | 2021-2025 | 40 | GB 2 | 95.64 |
| Immunotherapy and Immune Responses | 2021-2025 | 184 | GB 2 | 97.22 |
| Cancer Research and Treatments | 2021-2025 | 59 | GB 3 | 96.02 |
| CAR-T cell therapy research | 2021-2025 | 271 | GB 3 | 98.14 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 263 | GB 8 | 98.28 |
| Brain Metastases and Treatment | 2021-2025 | 388 | GB 3 | 90.65 |
| Cancer-related Molecular Pathways | 2021-2025 | 328 | GB 13 | 85.94 |
| Salivary Gland Tumors Diagnosis and Treatment | 2021-2025 | 616 | GB 19 | 79.78 |
| Chromatin Remodeling and Cancer | 2021-2025 | 957 | GB 36 | 53.84 |